Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Prudential Financial, Inc. (PFI) has filed Amendment No. 2 to Schedule 13G for Cabaletta Bio, Inc. (NASDAQ: CABA). As of 30 June 2025, PFI reports beneficial ownership of 10,391,167 common shares, representing 7.4 % of CABA’s outstanding stock. All shares are held with shared voting and dispositive power; PFI claims no sole authority over the shares.
The position is held through two investment-management subsidiaries: Jennison Associates LLC (10,107,167 shares; 7.2 %) and PGIM, Inc. (284,000 shares; 0.2 %). PFI classifies itself as a “parent holding company/ control person” under Rule 13d-1(b)(1)(ii)(G) and certifies the shares are held in the ordinary course of business, not to influence control of Cabaletta Bio.
Key takeaways for investors: 1) PFI remains a >5 % holder, indicating continued institutional support; 2) the stake size affords PFI meaningful, though not controlling, influence in shareholder matters; 3) no sale intention or activist purpose is disclosed.
Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.
Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.